Home/Pipeline/Undisclosed Antibody Programs (Oncology)

Undisclosed Antibody Programs (Oncology)

Solid tumors

Pre-clinicalActive

Key Facts

Indication

Solid tumors

Phase

Pre-clinical

Status

Active

Company

AryoGen Pharmed

About AryoGen Pharmed

AryoGen Pharmed is a private, early‑stage Israeli biopharmaceutical company building a pipeline of next‑generation antibody‑based therapies. Its internal discovery platform enables the rapid generation of fully human monoclonal antibodies and antibody‑drug conjugates for difficult‑to‑treat cancers and immune disorders. With $30 million raised to date, the company is advancing multiple preclinical programs toward the clinic and exploring strategic partnerships.

View full company profile

Therapeutic Areas

Oncology Immunology

Other Solid tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
Undisclosed ADC Programs (Oncology)	AryoGen Pharmed	Pre-clinical	Active
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed